E-cadherin and Integrin Alpha v Beta 1 in Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to study the effect of Narrow Band UVB on E-cadherin and integrin alpha v beta 1 as representatives of adhesion molecules in non-segmental vitiligo in a trial to verify a novel proposed mechanism of Narrow Band UVB. Additionally, specific melanocyte marker (Melan A) will be done to settle the localization of adhesion molecules in relation to melanocytes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Beta-defensin 1 in Vitiligo

NCT03832751

Vitiligo

UNKNOWN NA

Vitiligo, New Treatment and Serum s100B

NCT06768840

Vitiligo, Generalized

RECRUITING PHASE2/PHASE3

Histochemical Study of Vitiligo in Sohag University Hospital Patients

NCT05869942

Vitiligo

UNKNOWN NA

Sensory Symptoms in Active Vitiligo

NCT05390164

Totest Sensory Symptoms in Active Vitiligo

UNKNOWN

Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo

NCT05812079

Vitiligo

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

15 patients with vitiligo subjected to NB-UVB

Patients will be subjected to NB-UVB sessions 3 times weekly. The UVB dosing scheme in the patients receiving only NB-UVB treatment entailed initial dosing at 0.5 J/cm2 with increasing increments by 0.3 J/cm 2 every other session until faint erythema occurs.

Group Type EXPERIMENTAL

Narrow band UVB

Intervention Type DEVICE

Narrow band UVB emitting UVB at wavelength 311nm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Narrow band UVB

Narrow band UVB emitting UVB at wavelength 311nm

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All clinically diagnosed cases of non-segmental vitiligo .
* Patients with VIDA +1 or more (new/expanding lesions active in time period of 6-12 months ago) will be included in the trial. Activity of vitiligo will be evaluated through Vitiligo Disease Activity (VIDA) Score.

Exclusion Criteria

* Patients who have stable disease at the time of study i.e. no progression of existing disease or appearance of new lesions in the last six months.
* Patients receiving treatment for vitiligo 3 months prior to the study.
* Patients with contraindications for phototherapy.
* Patients with current/history of any systemic and/or dermatological diseases affecting the immune system as autoimmune diseases and malignancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes